Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease

(2013) Y. Inamoto et al.   BLOOD

Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease

(2013) Y. Inamoto et al.   BLOOD

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD

(2012) A. de Masson et al.   BLOOD

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium

(2012) D. A. Jacobsohn et al.   BLOOD

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change

(2011) Sandra A. Mitchell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

(2011) G. L. Chen et al.   BLOOD

Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease

(2011) K. J. Martires et al.   BLOOD

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

(2011) J. Pidala et al.   BLOOD

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria

(2011) S. Arai et al.   BLOOD

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

(2011) Jacopo Olivieri et al.   TheScientificWorldJOURNAL

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease

(2010) Daniel Wolff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease

(2009) M. Stadler et al.   BLOOD

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

(2009) L. Magro et al.   BLOOD

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

(2009) A. Olivieri et al.   BLOOD

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

(2008) M. E. D. Flowers et al.   BLOOD

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

(2008) Alfiya Akhmetshina et al.   FASEB JOURNAL

Feasibility of NIH consensus criteria for chronic graft-versus-host disease

(2008) B-S Cho et al.   LEUKEMIA